Study Title

Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Study Details

Description:

A multicenter Phase II, randomized, prospective, open-label Trial investigating the clinical impact on combining Specific Internal Radiotherapy (SIRT) with the PD1-L Inhibitor Durvalumab and the CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer

Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Contacts:

Arndt Vogel, Professor

vogel.arndt@mh-hannover.de

+49 511 5326 ext 760

Doerthe Vortmeyer, Doctor

vortmeyer.doerthe@ikf-khnw.de

+49 069 7601 ext 4196

Government Study Link:

NCT04238637 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468